|
INN ▲
|
ATC Code ▲
|
Country ▲
|
Classification ▲
|
Last update ▲
|
MA Number ▲
|
Registration date ▲
|
Status ▲
|
|
FINERENONE |
C03DA05 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/005200 |
16-02-2022 |
VALID
|
|
ISAVUCONAZOLE |
J02AC05 |
DE
|
POM
|
25-04-2022 |
|
|
VALID
|
|
LONAPEGSOMATROPIN |
H01AC09 |
DE
|
Not authorised
|
25-04-2022 |
|
|
VALID
|
|
PEGCETACOPLAN |
L04AJ03 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/005553 |
13-12-2021 |
VALID
|
|
PNEUMOCOCCUS, PURIFIED POLYSACCHARIDES ANTIGEN CONJUGATED |
J07AL02 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/005451 |
14-02-2022 |
VALID
|
|
PRALSETINIB |
L01EX23 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/005413 |
18-11-2021 |
VALID
|
|
REGDANVIMAB |
J06BD06 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/005854 |
12-11-2021 |
VALID
|
|
RIPRETINIB |
L01EX19 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/005614 |
18-11-2021 |
VALID
|
|
SACITUZUMAB GOVITECAN |
L01FX17 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/005182 |
22-11-2021 |
VALID
|
|
SEMAGLUTIDE |
A10BJ06 |
DE
|
POM
|
25-04-2022 |
|
|
VALID
|
|
SOMATROGON |
H01AC08 |
DE
|
Not authorised
|
25-04-2022 |
|
|
VALID
|
|
SOTROVIMAB |
J06BD05 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/005676 |
17-12-2021 |
VALID
|
|
TECOVIRIMAT |
J05AX24 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/005248 |
06-01-2022 |
VALID
|
|
TIGECYCLINE |
J01AA12 |
DE
|
POM
|
25-04-2022 |
|
|
VALID
|
|
VOXELOTOR |
B06AX03 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/004869 |
14-02-2022 |
VALID
|
|
ZANUBRUTINIB |
L01EL03 |
DE
|
POM
|
25-04-2022 |
EMEA/H/C/004978 |
22-11-2021 |
VALID
|
|
ACALABRUTINIB |
L01EL02 |
DE
|
POM
|
26-04-2022 |
|
|
VALID
|
|
BRIGATINIB |
L01ED04 |
DE
|
POM
|
26-04-2022 |
|
|
VALID
|
|
CRIZANLIZUMAB |
B06AX01 |
DE
|
POM
|
26-04-2022 |
|
|
VALID
|
|
LETERMOVIR |
J05AX18 |
DE
|
POM
|
26-04-2022 |
|
|
VALID
|
|
PRASTERONE |
G03XX01 |
DE
|
POM
|
26-04-2022 |
|
|
VALID
|
|
UPADACITINIB |
L04AF03 |
DE
|
POM
|
26-04-2022 |
|
|
VALID
|
|
FERROUS SULFATE |
B03AA07 |
DE
|
Not subject to prescription
|
27-06-2022 |
DE/H/3789/001/ |
17-12-2014 |
VALID
|
|
CIPROFLOXACIN |
J01MA02 |
DE
|
POM
|
29-06-2022 |
DE/H/0587/001/II/001 |
25-02-2010 |
VALID
|
|
LEVOFLOXACIN |
J01MA12 |
DE
|
POM
|
11-07-2022 |
|
|
VALID
|
|
LITHIUM |
N05AN01 |
DE
|
POM
|
12-07-2022 |
DE/H/4351/001/ |
16-03-2016 |
VALID
|
|
MOXIFLOXACIN |
J01MA14 |
DE
|
POM
|
12-07-2022 |
DE/H/3966/001/ |
02-03-2015 |
VALID
|
|
NORFLOXACIN |
J01MA06 |
DE
|
POM
|
12-07-2022 |
DE/H/2420/001/II/001 |
07-05-2009 |
VALID
|
|
OFLOXACIN |
J01MA01 |
DE
|
POM
|
12-07-2022 |
DE/H/0317/001/II/013 |
16-11-2009 |
VALID
|
|
THIAMAZOLE |
H03BB02 |
DE
|
POM
|
12-07-2022 |
DE/H/0521/002/ |
03-08-2012 |
VALID
|
|
DARUNAVIR |
J05AE10 |
DE
|
POM
|
21-11-2022 |
|
|
VALID
|
|
AZELASTINE |
S01GX07 |
DE
|
Not subject to prescription
|
23-02-2023 |
DE/H/3852/001/ |
17-11-2014 |
VALID
|
|
EMEDASTINE |
S01GX06 |
DE
|
POM
|
23-02-2023 |
|
|
VALID
|
|
ASCIMINIB |
L01EA06 |
DE
|
POM
|
27-02-2023 |
|
|
VALID
|
|
ATIDARSAGENE AUTOTEMCEL |
A16AB21 |
DE
|
POM
|
27-02-2023 |
|
|
VALID
|
|
AVALGLUCOSIDASE ALFA |
A16AB22 |
DE
|
POM
|
27-02-2023 |
EMEA/H/C/005501 |
24-06-2022 |
VALID
|
|
CAPMATINIB |
L01EX17 |
DE
|
POM
|
27-02-2023 |
EMEA/H/C/004845 |
20-06-2022 |
VALID
|
|
CILTACABTAGENE AUTOLEUCEL |
L01XL05 |
DE
|
POM
|
27-02-2023 |
|
|
VALID
|
|
DIFELIKEFALIN |
V03AX04 |
DE
|
POM
|
27-02-2023 |
EMEA/H/C/005612 |
25-04-2022 |
VALID
|
|
EFGARTIGIMOD ALFA |
L04AA58 |
DE
|
POM
|
27-02-2023 |
EMEA/H/C/005849 |
10-08-2022 |
VALID
|
|
ENFORTUMAB VEDOTIN |
L01FX13 |
DE
|
POM
|
27-02-2023 |
EMEA/H/C/005392 |
13-04-2022 |
VALID
|
|
FARICIMAB |
S01LA09 |
DE
|
POM
|
27-02-2023 |
|
|
VALID
|
|
FOSDENOPTERIN |
A16AX19 |
DE
|
POM
|
27-02-2023 |
|
|
VALID
|
|
INEBILIZUMAB |
L04AG10 |
DE
|
POM
|
27-02-2023 |
EMEA/H/C/005818 |
25-04-2022 |
VALID
|
|
LASMIDITAN |
N02CC08 |
DE
|
POM
|
27-02-2023 |
|
|
VALID
|
|
LENACAPAVIR |
J05AX31 |
DE
|
POM
|
27-02-2023 |
|
|
VALID
|
|
LINZAGOLIX |
H01CC04 |
DE
|
POM
|
27-02-2023 |
EMEA/H/C/005442 |
14-06-2022 |
VALID
|
|
LONAFARNIB |
A16AX20 |
DE
|
POM
|
27-02-2023 |
|
|
VALID
|
|
MELPHALAN FLUFENAMIDE |
L01AA10 |
DE
|
POM
|
27-02-2023 |
EMEA/H/C/005681 |
17-08-2022 |
VALID
|
|
NIVOLUMAB AND RELATLIMAB |
L01FY02 |
DE
|
POM
|
27-02-2023 |
EMEA/H/C/005481 |
15-09-2022 |
VALID
|
